Therapeutic Response Statement (Sensitivity)
This therapeutic response statement supports the relationship that BRAF p.V600E status confers therapeutic sensitivity to Binimetinib, Encorafenib in patients with Non-Small Cell Lung Cancer.
The European Medicines Agency (EMA) has authorized binimetinib in combination with encorafenib for the treatment of adult patients with advanced non-small cell lung cancer with a BRAF V600E mutation.
This statement is based on a regulatory approval from the European Medicines Agency:
Binimetinib in combination with encorafenib is indicated for the treatment of adult patients with advanced non-small cell lung cancer with a BRAF V600E mutation.